Address: H-1027 BUDAPEST, BUDA BUSINESS CENTER, KAPÁS UTCA 11-15.
Tel: +36 250-4876
Web: http://www.igy.hu/
The Association of Innovative Pharmaceutical Manufacturers (AIPM) established in 1992 comprises 27 research-based pharmaceutical firms in Hungary which account for 60 percent of the domestic medicine turnover in terms of value.
The mother companies of the member firms do pioneering work in researching and developing new, original preparations, with the aim of making a breakthrough in the therapy of diseases that can not be treated at all or that can not be treated with proper efficacy. In addition to their enormous intellectual investment our member companies spend significant amounts – exceeding several billions of dollars a year – to develop new, innovative medicines. Development of a single original preparation roughly costs as much as the annual pharmaceutical budget of the National Health Insurance Fund.
The innovative pharmaceutical companies play active role in fostering advanced professional education of Hungarian doctors and pharmacists. Our officially accredited training courses provide great help to doctors getting ready for their professional exams.
As well as playing a decisive role in the foreign and domestic pharmaceutical market the member companies of the Association principally contribute to the Hungarian clinical research and advance training of the doctors.
Owing to the good offices of our member companies and as a recognition of their professional knowledge Hungarian doctors already regularly take part in high level multicenter clinical trials of new original preparations carried out simultaneously in many countries under strictly identical conditions, preceded in every case by the evaluation and authorization of the National Institute of Pharmacy.
Over 80 percent of the pre-registration investigations considered to be most exacting have been started by AIPM member companies. Several firms brought their Central-Eastern European clinical research centers to Hungary.
In addition to the aforesaid, our member companies equip doctors with medical textbooks, written by independent authors recognized in their profession, support patient’s organizations and foundations. All these are being done in order to become partners in an increasingly effective treatment of the Hungarian patients.
With various new government measures, the pharmaceutical and healthcare sector in Hungary has been undergoing quite a turbulent period recently. But if we first take a step back… Can you…
The managing director of Wörwag Pharma Hungary, Dr. Éva Kádár depicts the company’s impressive evolution, highlighting the expansive network of neuropathy centers that they’ve helped establish all over Hungary and…
Soneas MD Jozsef Repasi discusses the shift back towards Central and Eastern Europe for contract manufacturing services, the company’s growth since separating from Ubichem, and his ambitions for Soneas to…
AmCham Hungary, one of the largest American Chambers of Commerce in Central and Eastern Europe, discusses their advocacy efforts, particularly highlighting the chamber’s recently established Healthy Nation Policy Task Force…
Hungary has long boasted a vibrant, skilled pharmaceutical industry that continues to attract the interest of local and multinational entities alike. This fact was highlighted today at the celebration of GlaxoSmithKline’s…
The managing director of CSL Behring Hungary, Attila Lukács, discusses the company’s recent establishment in Hungary, the strategic benefits the country offers, as well as his experience starting an affiliate…
Meda Pharma Hungary GM Dr. Laszlo Gaspar describes how the strategic shift from Rx to OTC has allowed the company to experience year-on-year growth over the last eight years and…
The country manager of Berlin-Chemie / A. Menarini Hungary, Dr. Peter Olah, explains the impact of a more targeted sales force in driving the company in the last three years,…
Agnès Ducrot and Miklos Maróthy of CCI France Hongrie discuss their advocacy efforts in Hungary and the history of French investment in the country. They also discuss the challenges and opportunities…
The general manager of IMS Health, Zsolt Szepesházi, explains how the current limitations of Hungary’s healthcare system have shifted the way that pharmaceutical companies approach the market, placing a much…
Novo Nordisk Hungary GM Zsolt Jozsa highlights the growing prevalence of diabetes in Hungary, the gap in treatment options that the company is striving to close with Tresiba and Xultophy,…
The managing director of Janssen Hungary, Andreas Woitossek, depicts the valuable role of real-world evidence in enabling the affiliate’s consistent double-digit growth over the last four years, while highlighting the…
With various new government measures, the pharmaceutical and healthcare sector in Hungary has been undergoing quite a turbulent period recently. But if we first take a step back… Can you…
See our Cookie Privacy Policy Here
